Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Obama - Clinton Disaster -- Ignore unavailable to you. Want to Upgrade?

To: PROLIFE who wrote (67619)	3/15/2012 5:29:35 AM
From: GROUND ZERO™	1 Recommendation Read Replies (1) \| Respond to of 103300

Oil company profits are meager compared to the pharmaceutical companies or the computer software companies or the cruise lines companies, so all that piece of camel shit is doing is reciting the "poor me" and "pity me" and "let's blame the rich guy" mantras of the uninformed and of the uneducated trailer park mentality about life in the real world, but the people with that kind of mentality are his voting base... frankly, blaming the wealthy for the condition of the poor is exactly what that video explains, oscumbag is nothing but a traitor and a shill for the anti colonialists of the world who are too lazy to earn their own way and prefer to blame others for their failings... if you think about it, this is exactly his MO since day one... GZ

To: PROLIFE who wrote (67619)	3/16/2012 2:42:50 PM
From: Hope Praytochange	3 Recommendations Read Replies (1) \| Respond to of 103300

under odumbama: March 16, 2012, 12:48 p.m. ET For Biotech Firms, Gravy Days Are Over BY JONATHAN D. ROCKOFF AND PUI-WING TAM Biotechnology firms are coming around to a harsh reality: The gravy days are over. These small, innovative drug companies were once an investment darling, able to secure millions of dollars from venture capitalists and even more later through public offerings. But in recent years, venture financing for biotech has been in decline, due to the tough economic environment and poor returns from stock offerings. Venture capitalists invested a total of $3.92 billion last year in biotechs of all stages, well below the $6.17 billion peak in 2007, according to VentureSource.